NBXTR3 Plus Radio/ICI Shows Promising Results in Melanoma TrialByJason Chan, MD,Sabrina SeraniOctober 8th 2025A phase 1 study reveals promising safety and efficacy of NBTXR3 combined with radiotherapy and immunotherapy for resistant melanoma patients.